Fortis Malar Hospitals Limited (the "Company"), a subsidiary of **Fortis Healthcare Limited**, has undergone a fundamental structural transformation. Following a strategic divestment in early **2024**, the company has transitioned from an active tertiary healthcare provider to a listed entity with **no current business operations**. The company is currently in a "shell" state, focused on managing legacy litigations and evaluating corporate restructuring options for the distribution of surplus capital. --- ### **Strategic Divestment & Current Business Status** Historically, the company operated a **140-bed** (expandable to **160**) multi-specialty hospital in Chennai. Due to persistent legacy litigation and regularization issues surrounding the hospital building (owned by fellow subsidiary **FHML**), management executed a complete exit from the operating business to protect shareholder value. * **The Transaction:** Sale of business operations via a **Business Transfer Agreement (BTA)** to **MGM Healthcare Private Limited**. * **Structure:** Slump sale as a going concern on an **all-cash** basis. * **Consideration:** **INR 45.72 crore**. * **Effective Date:** **February 01, 2024**. * **Operational Status:** As of the effective date, the company ceased all healthcare delivery. There is currently **no immediate visibility** for commencing new business operations. * **Registered Office:** Shifted from Chennai to **Mohali, Punjab**. --- ### **Corporate Structure & Ownership Ecosystem** The company is a key node within the **IHH Healthcare Berhad (Malaysia)** ecosystem, following IHH’s acquisition of a controlling stake in the parent group. | Entity | Relationship | | :--- | :--- | | **IHH Healthcare Berhad** | Ultimate Holding Company (via NTK Venture Pte Ltd) | | **Fortis Healthcare Limited** | Intermediate Holding Company | | **Fortis Hospitals Limited** | Immediate Holding Company (**62.71%** stake) | | **Fortis Healthcare Research Foundation** | Wholly-owned Subsidiary (Converted to Section 8 Company) | **The Mandatory Open Offer:** Triggered by the IHH acquisition, an open offer by **Northern TK Venture Pte Ltd** to acquire **4,894,308** shares (**26%** of capital) was completed on **November 10, 2025**. * **Final Offer Price:** **INR 17.60** per share (Adjusted downward from **INR 60.10** following a massive **INR 40** interim dividend). * **Interest Component:** An additional **INR 18.36** per share was paid to original shareholders due to the delay caused by prior Supreme Court status quo orders. --- ### **Legacy Clinical & Technological Framework** While operations have ceased, the company’s historical framework was built on high-end clinical outcomes and digital integration. These assets and methodologies were part of the transfer to the acquirer: * **Clinical Benchmarking:** First hospital in Chennai to monitor **Clinical Outcomes** based on global evidence-based metrics and **Patient-Reported Outcomes Measurement (PROM)**. * **Digital Infrastructure:** Implementation of **Electronic Health Records (EHR)**, **Clinical Decision Support Systems (CDSS)**, and **Telemedicine** platforms. * **Advanced Tech:** Integration of **robot-assisted surgery**, **AI/Machine Learning** for disease risk scoring (in partnership with **Microsoft**), and exploration of **Blockchain** for secure medical records. --- ### **Financial Profile & Capital Distribution** The company’s financial statements now reflect a non-operating entity with significant cash reserves and minimal revenue. **Comparative Financial Performance (Summary Table):** | Metric (INR Crore) | FY 2024-25 | FY 2023-24 | FY 2022-23 | | :--- | :---: | :---: | :---: | | **Total Income** | **2.72** | **65.96** | **92.59** | | **EBITDA** | **0.58** | **5.75** | **11.21** | | **Profit After Tax** | **0.39** | **45.32*** | **(15.48)** | *\*FY24 PAT includes a net gain of **INR 47.22 crore** from the slump sale recorded as an exceptional item.* **Liquidity & Shareholder Returns:** * **Inter-Corporate Deposits (ICD):** **INR 68 crore** previously extended to Fortis Healthcare Limited was fully repaid in **February 2024**. * **Dividends:** Following the divestment, the company distributed a total of **INR 42.5 per share** (**INR 40** interim in April 2024 and **INR 2.5** final in July 2024). * **Cash Position:** As of **February 2026**, the company maintains a cash balance of approximately **INR 32.52 crore**, intended to cover administrative costs and potential legal liabilities. --- ### **Risk Matrix & Contingent Liabilities** The primary risks have shifted from operational healthcare risks to **litigation and regulatory risks** associated with the company's past. **1. Significant Contingent Liabilities:** The company is contesting several high-value demands. While management views the risk of outflow as remote, the following remain active: * **GST Adjudication:** A proposed demand of **INR 225.35 crore** (for 2017-2023) was successfully contested and reduced to **INR 22.23 lakhs**; however, further notices totaling **INR 153.10 crore** are being monitored. * **Income Tax Appeals:** Contested demands totaling **INR 171.43 crore** (historical) and a specific outstanding demand of **INR 1.51 crore**. * **Medico-Legal Cases:** Claims pending in various Consumer Commissions totaling approximately **INR 6.49 crore**. * **VAT Appeals:** **INR 2.55 crore** related to the taxability of medical implants (2008-2012). **2. Strategic & Governance Risks:** * **Lack of Revenue:** There is no active business to generate top-line growth. * **Restructuring Uncertainty:** While the Board is evaluating options with merchant bankers, there is no fixed timeline for a merger, liquidation, or new business commencement. * **Indemnities:** Under the BTA, the company provided warranties to MGM Healthcare capped at **100% of the purchase consideration** (**INR 45.72 crore**). No claims have been filed as of **March 31, 2025**. --- ### **Governance & Listing Information** * **Listing:** Actively traded on **BSE Limited** (**ISIN: INE842B01015**). * **Dematerialization:** **97.54%** of equity is held in electronic form. * **Key Personnel:** * **Mr. Daljit Singh**: Chairman. * **Mr. Bidesh Chandra Paul**: Whole-time Director (Appointed through **February 2029**). * **Reporting Segment:** Continues to report under a single segment (**Healthcare Services**) despite the cessation of active hospital operations, as it finalizes its corporate future.